Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Change in lean mass during pharmacologically induced weight reduction — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-006/5
Series
Evidence synthesis
Version
3.0
Published
17 Jul 2024
Last reviewed
17 Mar 2025
Next review
17 Sep 2026
Identifier
10.71829/cei.syn.6
Certainty
Low
Cycle
2024 Q3
Review type
Scoping review
Search executed
12 Apr 2024

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
28 May 20240.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
17 Jan 20252.1Analysis method changedThe pooling method was changed from a fixed-effect to a random-effects model following observation of between-study heterogeneity exceeding the pre-specified threshold.
19 Apr 20253.2Certainty rating revisedThe certainty rating for one outcome was revised following the addition of a contributing study. The rationale is recorded in the certainty assessment section.
21 Jun 20253.3Search re-runThe search was re-run to the current cycle date. Newly identified records were screened against the registered criteria without modification of those criteria.
09 Oct 20253.0Analysis method changedThe pooling method was changed from a fixed-effect to a random-effects model following observation of between-study heterogeneity exceeding the pre-specified threshold.
03 Mar 20263.1Certainty rating revisedThe certainty rating for one outcome was revised following the addition of a contributing study. The rationale is recorded in the certainty assessment section.
Current version 3.0, ratified in the 2024 Q3 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
SURMOUNT-531 Mar 2024No response
SURMOUNT-KOA08 Mar 2024Refused
SUMMIT12 Mar 2024Refused
SURMOUNT-415 Mar 2024No response
SURMOUNT-OSA-128 Feb 2024Redirected to a data-access portal
SURMOUNT-OSA-227 Mar 2024Redirected to a data-access portal
SELECT30 Mar 2024Refused
STEP-HFpEF17 Mar 2024Supplied on request

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.